Navigation Links
Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
Date:10/24/2007

BERKELEY HEIGHTS, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that clinical data from the Company's programs for Genasense(R) (oblimersen) in patients with advanced melanoma will be featured at the 4th International Melanoma Congress. The conference will take place at the New York Marriott Financial Center Hotel, New York, NY from November 1-4, 2007. A poster session featuring the Genasense data will take place on Thursday November 1 from 8-10 am EDT.

Titles and authors include the following:

Progression-free survival (PFS) with an oblimersen-dacarbazine regimen in advanced melanoma: PFS difference is not explained by assessment asymmetry. Presenter: E. Gilles.

Overview of the AGENDA Study: A randomized, double-blind study of Genasense plus dacarbazine in chemotherapy-naive patients with advanced melanoma and low LDH. Presenter: A. Bedikian.

A Phase I study of the triple combination of oblimersen, temozolomide, and Abraxane in patients with advanced melanoma and normal LDH. Presenter: A. Pavlick.

Pharmacokinetics of oblimersen in combination with dacarbazine in metastatic melanoma: randomized intra-subject evaluation. Presenter: D. Kerob.

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversif
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015 Nortek Security ... NTK ) and a leader in the ... today announced it acquired mobile personal emergency response ... held Numera, Inc. Headquartered in ... easily implemented, mobile PERS products and cloud-based software ...
(Date:6/30/2015)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a ... today announced it has submitted its fifth abbreviated new ... Administration (FDA) of 2015, which brings the Company,s total ... to twenty-seven. Jason Grenfell-Gardner , President ... current pipeline of twenty-seven submissions, exclusive of our four ...
(Date:6/30/2015)... new way for people to keep their family safe, while ... is being introduced to the world via an Indiegogo ... $70,000, which needs to be raised in order to bring ... device was inspired by the many scenarios people face in ... day. While medical alert bracelets have been around for years, ...
Breaking Medicine Technology:Nortek Security & Control Acquires Health and Wellness Technology Business from Numera 2Nortek Security & Control Acquires Health and Wellness Technology Business from Numera 3Nortek Security & Control Acquires Health and Wellness Technology Business from Numera 4IGI Laboratories, Inc. Announces Fifth ANDA Submission Of 2015 2Amyko Propels Medical Alert Bracelets Into the Modern Era 2
... , DENVER , Feb. 11 ... and marketer of diagnostic test kits, today filed its 2nd quarter ... the company,s revenues slightly declined during the quarter but slightly increased ... of the results highlighted by the report are as follows: , ...
... MOUNTAIN VIEW, Calif. , Feb. 11 Alexza Pharmaceuticals, ... & Drug Administration has accepted the AZ-004 NDA for filing and ... of October 11, 2010 .  Alexza filed the AZ-004 NDA ... for the rapid treatment of agitation in patients with schizophrenia or ...
Cached Medicine Technology:Corgenix Reports Second Quarter Fiscal 2010 Financial Results 2Corgenix Reports Second Quarter Fiscal 2010 Financial Results 3Corgenix Reports Second Quarter Fiscal 2010 Financial Results 4Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010 2Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010 3
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... Good Neighbor Pharmacy’s premier event and tradeshow, taking place July 29 to August ... purchasing decision makers. , ThoughtSpot is a four-day event for independent ...
(Date:6/30/2015)... ... June 30, 2015 , ... University Post-Acute Rehab recently ... on the rehab center’s patients and their experiences at the facility. Medicare granted ... services available. Each patient attests to the high rating, which is predominantly based ...
(Date:6/30/2015)... ... June 30, 2015 , ... Broadway by the Sea posted its newest ... family member testimonials. Medicare rated the care center as a five-star location based on ... to give future patients a firsthand look at the facility’s satisfied residents. , ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... in a federal multidistrict litigation now underway in the U.S. District Court, Eastern ... Status Conference. According to the Court’s calendar, that conference has now been scheduled ...
(Date:6/30/2015)... ... June 30, 2015 , ... Allied Anesthesia physicians are committed ... volunteered to help provide free outpatient procedures to some of Orange County’s neediest ... Medical Center. , The event was coordinated by AccessOC, which was founded ...
Breaking Medicine News(10 mins):Health News:Retail Management Solutions to Attend Amerisource's ThoughtSpot 2015 Conference and Trade Show 2Health News:Retail Management Solutions to Attend Amerisource's ThoughtSpot 2015 Conference and Trade Show 3Health News:Patients of University Post-Acute Rehab Support Five-Star Rating in New Video 2Health News:Broadway by the Sea Video Promotes Top Quality Service 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 3
... Inc. and Onyx Pharmaceuticals, Inc. today announced that ... patients with hepatocellular carcinoma (HCC), or primary ... Results were presented at the 43rd annual meeting ... ,The international, Phase 3, placebo-controlled Sorafenib ...
... holding the state to ransom with businesses, including pharmacies, ... slapped by rebels. ,Pharmacies across the state ... a rebel group demanded Rs.10 million ($247,000) as 'tax' ... All Manipur Pharmaceutical and Druggists Association. ...
... today announced details of two new investigational cancer therapies ... AZD2281 (KU-0059436) is a small molecule inhibitor of ... enzyme involved in Base Excision Repair which is a ... Inhibiting this DNA repair mechanism, in tandem with a ...
... known as a poison that can kill, arsenic also can ... leukemia , a new study out Saturday found. ... we give (arsenic) earlier in the course of treatment," said ... in North Carolina, and the lead author of the research ...
... 2007 An international team led by MUHC has identified ... a common congenital blindness in infants and small children. ... Genetics and is partly funded by the Foundation Fighting Blindness ... to fast-track a cure for this disease, says lead investigator ...
... CHICAGO The last two decades have seen modest overall ... disease . However, according to researchers at The University of ... improvement in the rates for black women; differences in life ... ,The study, presented today (June 3) at the 43rd ...
Cached Medicine News:Health News:Nexavar Significantly Extends Survival of Liver Cancer Patients 2Health News:Manipur Pharmacies Shut Down Fearing Separatist Threats 2Health News:Astrazeneca's Investigational Cancer Therapies Revealed at ASCO 2Health News:Astrazeneca's Investigational Cancer Therapies Revealed at ASCO 3Health News:Gene Responsible for Blindness in Infants and Children Identified 2Health News:Advanced Breast Cancer: Study Reveals White and Black Women Have Different Survival Rates 2
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
... Amvex offers a complete line ... heliox and CO 2 . They ... of calibrations to best suit your ... dials specific to the gas in ...
... Amvex offers a complete line ... heliox and CO 2 . They ... of calibrations to best suit your ... dials specific to the gas in ...
... Amvex offers a complete line of flowmeters, available ... are all available in a variety of calibrations to ... dials specific to the gas in use, the Amvex ... colors replace the U with I. For Power Take-Off ...
Medicine Products: